A clinical study has found significant benefits of EDTA Chelation for diabetic patients with prior myocardial infarctions.
The sub-study of the major Trial to Assess Chelation Therapy (TACT) was presented at the American Heart Association Scientific Sessions in November 2013, and published in Circulation: Cardiovascular and Quality Outcomes. Read the abstract or download the full article (11 page PDF, 1.2MB).
The paper concludes: “Post–myocardial infarction patients with diabetes mellitus aged ≥50 demonstrated a marked reduction in cardiovascular events with EDTA chelation. These findings support efforts to replicate these findings and define the mechanisms of benefit. However, they do not constitute sufficient evidence to indicate the routine use of chelation therapy for all post–myocardial infarction patients with diabetes mellitus.”
Reacting to the study, an article ‘Chelation Therapy: Promising For Diabetic Patients but Disruptive to the Medical Establishment’ by John Mandrola in Medscape, 20 November 2013 (requires registration) notes:
“Based on this analysis of TACT, only six patients with diabetes had to be treated with chelation to prevent one adverse outcome. That’s less than half the NNT [number needed to treat] when statins are used in patients with diabetes and established vascular disease – an uncontroversial indication. Yet the medical establishment is overcome with doubt.”
“[TACT principal investigator] Dr Lamas told me that the favourable results of chelation do not surprise its practitioners. It’s what they have observed for years. What’s more, in the present subanalysis, researchers carefully looked at results based on [treatment clinic] sites and found no significant variance between CAM sites and ‘regular’ medical practices.”
A companion article “‘Extraordinary” Chelation Effects in Diabetes Propel TACT into Spotlight Again’ by Shelley Wood in Medscape, 19 November 2013 (requires registration) adds:
“Lamas acknowledged that cardiologists have greeted the TACT results with skepticism and/or derision but argues that the results are actually intuitive for diabetologists and epidemiologists, who over years of researching diabetes complications have demonstrated that accumulation of advanced-glycation end products involved metal-catalyzed oxygen chemistry for their formation. As such, chelation of metal ions may be that much more important in diabetes patients, explaining the magnitude of benefit in this group. Indeed, note Lamas and colleagues in their paper, some common diabetes medications actually have chelating properties.”
The information provided here is only for general reference and cannot replace personalised professional medical advice from a doctor. You are welcome to discuss any points during your consultation with our doctors.